| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5914122 | SALIX | Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams |
Dec, 2015
(8 years ago) | |
| US7410651 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Jun, 2020
(3 years ago) | |
| USRE43799 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Jun, 2020
(3 years ago) | |
| US9532954 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US10064878 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US9320716 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US10105374 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US10143698 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US8784888 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Jun, 2020
(3 years ago) | |
| US8293273 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Jun, 2020
(3 years ago) | |
| US7431943 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US8895064 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US9132093 | SALIX | Controlled release and taste making oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US9192581 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US10660858 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US10307375 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
Uceris is owned by Salix.
Uceris contains Budesonide.
Uceris has a total of 16 drug patents out of which 11 drug patents have expired.
Expired drug patents of Uceris are:
- US5914122
- US7410651
- USRE43799
- US9532954
- US10064878
- US9320716
- US10105374
- US10143698
- US8784888
- US8293273
- US7431943
Uceris was authorised for market use on 07 October, 2014.
Uceris is available in tablet, extended release;oral, aerosol, foam;rectal dosage forms.
Uceris can be used as induction of remission in patients with active, mild to moderate ulcerative colitis.
The generics of Uceris are possible to be released after 07 September, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2017 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 07 October, 2014
Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis
Dosage: AEROSOL, FOAM;RECTAL; TABLET, EXTENDED RELEASE;ORAL
UCERIS family patents
